These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2862829)

  • 1. Interactions of cholecystokinin and dopamine in the nucleus accumbens.
    Wang RY; White FJ; Voigt MM
    Ann N Y Acad Sci; 1985; 448():352-60. PubMed ID: 2862829
    [No Abstract]   [Full Text] [Related]  

  • 2. Interactions of cholecystokinin octapeptide and dopamine on nucleus accumbens neurons.
    White FJ; Wang RY
    Brain Res; 1984 May; 300(1):161-6. PubMed ID: 6145498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholecystokinin potentiation of dopamine-mediated behaviors in the nucleus accumbens.
    Crawley JN
    Ann N Y Acad Sci; 1985; 448():283-92. PubMed ID: 3861122
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of long-term haloperidol treatment on the responsiveness of accumbens neurons to cholecystokinin and dopamine: electrophysiological and radioligand binding studies in the rat.
    Debonnel G; Gaudreau P; Quirion R; de Montigny C
    J Neurosci; 1990 Feb; 10(2):469-78. PubMed ID: 2137531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuation of dark-induced hyperlocomotion by a cholecystokinin antagonist in the nucleus accumbens.
    Crawley JN
    Brain Res; 1988 Nov; 473(2):398-400. PubMed ID: 3233498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further studies on the specificity of proglumide as a selective cholecystokinin antagonist in the central nervous system.
    Bunney BS; Chiodo LA; Freeman AS
    Ann N Y Acad Sci; 1985; 448():345-51. PubMed ID: 2862828
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacological and mechanistic studies of cholecystokinin-facilitated [3H]dopamine efflux from rat nucleus accumbens.
    Vickroy TW; Bianchi BR
    Neuropeptides; 1989 Jan; 13(1):43-50. PubMed ID: 2466220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperpolarizing and depolarizing actions of dopamine via D-1 and D-2 receptors on nucleus accumbens neurons.
    Uchimura N; Higashi H; Nishi S
    Brain Res; 1986 Jun; 375(2):368-72. PubMed ID: 2942222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonism of cholecystokinin function in the rostral and caudal nucleus accumbens: differential effects on brain stimulation reward.
    Vaccarino FJ; Vaccarino AL
    Neurosci Lett; 1989 Feb; 97(1-2):151-6. PubMed ID: 2918999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiological evidence of modulatory interaction between dopamine and cholecystokinin in the nucleus accumbens.
    Yim CC; Mogenson GJ
    Brain Res; 1991 Feb; 541(1):12-20. PubMed ID: 2029612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrophysiological effects of cholecystokinin: central dopaminergic systems.
    Wang RY; White FJ
    Prog Clin Biol Res; 1985; 192():95-103. PubMed ID: 4080721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Injection of low doses of apomorphine into the nucleus accumbens of rats reduces locomotor activity.
    Van Ree JM; Wolterink G
    Eur J Pharmacol; 1981 Jun; 72(1):107-11. PubMed ID: 7262189
    [No Abstract]   [Full Text] [Related]  

  • 13. In vivo release of dopamine in the nucleus accumbens of the rat: modulation by cholecystokinin.
    Voigt MM; Wang RY
    Brain Res; 1984 Mar; 296(1):189-93. PubMed ID: 6324955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct properties of cholecystokinin-8 and mixed dopamine-cholecystokinin-8 neurons innervating the nucleus accumbens.
    Studler JM; Reibaud M; Tramu G; Blanc G; Glowinski J; Tassin JP
    Ann N Y Acad Sci; 1985; 448():306-14. PubMed ID: 3861123
    [No Abstract]   [Full Text] [Related]  

  • 15. Topographical analysis of nucleus accumbens sites at which cholecystokinin potentiates dopamine-induced hyperlocomotion in the rat.
    Crawley JN; Hommer DW; Skirboll LR
    Brain Res; 1985 Jun; 335(2):337-41. PubMed ID: 4005562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dopamine receptor agonists and antagonists in the rat nucleus acumbens [proceedings].
    Freedman SB; Wait CP; Woodruff GN
    Br J Pharmacol; 1979 Nov; 67(3):430P-431P. PubMed ID: 497555
    [No Abstract]   [Full Text] [Related]  

  • 17. Differential actions of substituted benzamides on pre- and postsynaptic dopamine receptor mechanisms in the nucleus accumbens.
    Costall B; Hui SC; Naylor RJ
    J Pharm Pharmacol; 1980 Aug; 32(8):594-6. PubMed ID: 6106706
    [No Abstract]   [Full Text] [Related]  

  • 18. Cholecystokinin antagonist lorglumide reverses chronic haloperidol-induced effects on dopamine neurons.
    Jiang LH; Kasser RJ; Wang RY
    Brain Res; 1988 Nov; 473(1):165-8. PubMed ID: 3208120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo electrochemical analysis of cholecystokinin-induced inhibition of dopamine release in the nucleus accumbens.
    Lane RF; Blaha CD; Phillips AG
    Brain Res; 1986 Nov; 397(1):200-4. PubMed ID: 3801862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A demonstration of the ability of apomorphine to act on dopamine receptors on nerve terminals in the nucleus accumbens to reduce locomotor hyperactivity [proceedings].
    Costall B; Hui SC; Naylor RJ
    Br J Pharmacol; 1979 Nov; 67(3):475P-476P. PubMed ID: 497587
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.